Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Clostridioides Difficile InfectionClostridium Difficile InfectionClostridium Difficile DiarrheaClostridia Difficile Colitis
Interventions
DRUG

Alanyl-glutamine

The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.

Trial Locations (2)

22903

RECRUITING

UVA Health Systems, Charlottesville

24014

RECRUITING

Carilion Clinic, Roanoke

All Listed Sponsors
collaborator

Carilion Clinic

OTHER

collaborator

University of Southampton

OTHER

lead

University of Virginia

OTHER